Innoviva, Inc. (INVA)
NASDAQ: INVA · Real-Time Price · USD
19.43
+0.07 (0.36%)
Nov 5, 2024, 4:00 PM EST - Market closed
Innoviva Revenue
Innoviva had revenue of $99.90M in the quarter ending June 30, 2024, with 23.34% growth. This brings the company's revenue in the last twelve months to $330.50M, up 13.80% year-over-year. In the year 2023, Innoviva had annual revenue of $310.46M, down -6.30%.
Revenue (ttm)
$330.50M
Revenue Growth
+13.80%
P/S Ratio
3.72
Revenue / Employee
$2,950,857
Employees
112
Market Cap
1.22B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 310.46M | -20.88M | -6.30% |
Dec 31, 2022 | 331.34M | -60.53M | -15.45% |
Dec 31, 2021 | 391.87M | 55.07M | 16.35% |
Dec 31, 2020 | 336.79M | 75.78M | 29.03% |
Dec 31, 2019 | 261.02M | 12.00K | 0.00% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Brookdale Senior Living | 2.92B |
Indivior | 1.18B |
Guardian Pharmacy Services | 1.12B |
U.S. Physical Therapy | 621.23M |
Alphatec Holdings | 572.74M |
ANI Pharmaceuticals | 538.95M |
CareDx | 297.08M |
Gyre Therapeutics | 111.59M |
INVA News
- 21 days ago - Innoviva Specialty Therapeutics to Present New Clinical Data From Its Development Pipeline and Broad Commercial Portfolio at IDWeek 2024 - Business Wire
- 2 months ago - Innoviva to Participate in Upcoming Investor Conferences - Business Wire
- 3 months ago - Innoviva Reports Second Quarter 2024 Financial Results; Highlights Recent Company Progress - Business Wire
- 5 months ago - Analyst Projects Strong Growth for GSK-Innoviva Partnered Respiratory Drugs - Benzinga
- 5 months ago - Innoviva to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference - Business Wire
- 6 months ago - Innoviva Reports First Quarter 2024 Financial Results; Highlights Recent Company Progress - Business Wire
- 6 months ago - Innoviva to Participate in the BofA Securities Health Care Conference - Business Wire
- 6 months ago - Innoviva Specialty Therapeutics' Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024 - Business Wire